世界の菌状息肉腫治療薬市場2021年-2025年

◆英語タイトル:Global Mycosis Fungoides Therapeutics Market 2021-2025
◆商品コード:IRTNTR70258
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年2月25日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社は世界の菌状息肉腫治療薬市場規模が、2021年~2025年まで年平均5%成長し、115.42百万ドルに達すると予測しています。本調査レポートでは、菌状息肉腫治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、種類別(小分子、生物製剤)分析、顧客状況、地域別状況、企業状況、企業分析などを掲載しております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の菌状息肉腫治療薬市場規模:種類別(小分子、生物製剤)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Mycosis Fungoides Therapeutics Market 2021-2025

Technavio has been monitoring the mycosis fungoides therapeutics market and it is poised to grow by $ 115.42 mn during 2021-2025, progressing at a CAGR of 5% during the forecast period. Our report on mycosis fungoides therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the special drug designations, recent drug approvals and growing incidence of mycosis fungoides. In addition, special drug designations is anticipated to boost the growth of the market as well.

The mycosis fungoides therapeutics market analysis includes type segment and geographical landscapes.

Technavio’s mycosis fungoides therapeutics market is segmented as below:
By Type
• Small molecules
• Biologics

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies the strong R&D of pipeline molecule as one of the prime reasons driving the mycosis fungoides therapeutics market growth during the next few years. Also, novel drug delivery system and increasing research funding will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on mycosis fungoides therapeutics market covers the following areas:
• Mycosis fungoides therapeutics market sizing
• Mycosis fungoides therapeutics market forecast
• Mycosis fungoides therapeutics market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading mycosis fungoides therapeutics market vendors that include Bristol-Myers Squibb Co., Eisai Co. Ltd., Helsinn Healthcare SA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Pfizer Inc., Seagen Inc., and Takeda Pharmaceutical Co. Ltd. Also, the mycosis fungoides therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/mycosis-fungoides-therapeutics-market-size-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Type
o Market segments
o Comparison by Type
o Small molecules – Market size and forecast 2020-2025
o Biologics – Market size and forecast 2020-2025
o Market opportunity by Type
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Competitive scenario
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Bristol-Myers Squibb Co.
o Eisai Co. Ltd.
o Helsinn Healthcare SA
o Hikma Pharmaceuticals Plc
o Horizon Therapeutics Plc
o Kyowa Kirin Co. Ltd.
o Merck & Co. Inc.
o Pfizer Inc.
o Seagen Inc.
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Type – Market share 2020-2025 (%)
• 22: Comparison by Type
• 23: Small molecules – Market size and forecast 2020-2025 ($ million)
• 24: Small molecules – Year-over-year growth 2020-2025 (%)
• 25: Biologics – Market size and forecast 2020-2025 ($ million)
• 26: Biologics – Year-over-year growth 2020-2025 (%)
• 27: Market opportunity by Type
• 28: Customer landscape
• 29: Market share by geography 2020-2025 (%)
• 30: Geographic comparison
• 31: North America – Market size and forecast 2020-2025 ($ million)
• 32: North America – Year-over-year growth 2020-2025 (%)
• 33: Europe – Market size and forecast 2020-2025 ($ million)
• 34: Europe – Year-over-year growth 2020-2025 (%)
• 35: Asia – Market size and forecast 2020-2025 ($ million)
• 36: Asia – Year-over-year growth 2020-2025 (%)
• 37: ROW – Market size and forecast 2020-2025 ($ million)
• 38: ROW – Year-over-year growth 2020-2025 (%)
• 39: Key leading countries
• 40: Market opportunity by geography ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: Bristol-Myers Squibb Co. – Overview
• 48: Bristol-Myers Squibb Co. – Product and service
• 49: Bristol-Myers Squibb Co. – Key offerings
• 50: Bristol-Myers Squibb Co. – Key customers
• 51: Bristol-Myers Squibb Co. – Segment focus
• 52: Eisai Co. Ltd. – Overview
• 53: Eisai Co. Ltd. – Business segments
• 54: Eisai Co. Ltd. – Key offerings
• 55: Eisai Co. Ltd. – Key customers
• 56: Eisai Co. Ltd. – Segment focus
• 57: Helsinn Healthcare SA – Overview
• 58: Helsinn Healthcare SA – Product and service
• 59: Helsinn Healthcare SA – Key offerings
• 60: Helsinn Healthcare SA – Key customers
• 61: Helsinn Healthcare SA – Segment focus
• 62: Hikma Pharmaceuticals Plc – Overview
• 63: Hikma Pharmaceuticals Plc – Business segments
• 64: Hikma Pharmaceuticals Plc – Key offerings
• 65: Hikma Pharmaceuticals Plc – Key customers
• 66: Hikma Pharmaceuticals Plc – Segment focus
• 67: Horizon Therapeutics Plc – Overview
• 68: Horizon Therapeutics Plc – Business segments
• 69: Horizon Therapeutics Plc – Key offerings
• 70: Horizon Therapeutics Plc – Key customers
• 71: Horizon Therapeutics Plc – Segment focus
• 72: Kyowa Kirin Co. Ltd. – Overview
• 73: Kyowa Kirin Co. Ltd. – Business segments
• 74: Kyowa Kirin Co. Ltd. – Key offerings
• 75: Kyowa Kirin Co. Ltd. – Key customers
• 76: Kyowa Kirin Co. Ltd. – Segment focus
• 77: Merck & Co. Inc. – Overview
• 78: Merck & Co. Inc. – Business segments
• 79: Merck & Co. Inc. – Key offerings
• 80: Merck & Co. Inc. – Key customers
• 81: Merck & Co. Inc. – Segment focus
• 82: Pfizer Inc. – Overview
• 83: Pfizer Inc. – Business segments
• 84: Pfizer Inc. – Key offerings
• 85: Pfizer Inc. – Key customers
• 86: Pfizer Inc. – Segment focus
• 87: Seagen Inc. – Overview
• 88: Seagen Inc. – Business segments
• 89: Seagen Inc. – Key offerings
• 90: Seagen Inc. – Key customers
• 91: Seagen Inc. – Segment focus
• 92: Takeda Pharmaceutical Co. Ltd. – Overview
• 93: Takeda Pharmaceutical Co. Ltd. – Product and service
• 94: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 95: Takeda Pharmaceutical Co. Ltd. – Key customers
• 96: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 97: Currency conversion rates for US$
• 98: Research Methodology
• 99: Validation techniques employed for market sizing
• 100: Information sources
• 101: List of abbreviations



【掲載企業】

Bristol-Myers Squibb Co., Eisai Co. Ltd., Helsinn Healthcare SA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Pfizer Inc., Seagen Inc., Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の菌状息肉腫治療薬市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆